Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL Clinical Trial
Official title:
A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
| Verified date | June 2022 |
| Source | SymBio Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
| Status | Completed |
| Enrollment | 40 |
| Est. completion date | December 31, 2019 |
| Est. primary completion date | December 31, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility | Inclusion criteria Patients who satisfy all of the conditions listed below. 1. Patients with histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) except for transformed lymphoma on the basis of World Health Organization (WHO) histological classification (4th ed., 2008). 2. Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells. 3. Patient with recurrent or relapsed DLBCL after R-CHOP-like theraphy as the firstline therapy. 4. Patients with measurable lesions >1.5 cm in major axes. 5. Patients who are expected to survive for at least 3 months. 6. Patients aged 20 or above at the time informed consent is obtained. 7. Patient with Performance Status (P.S.) 0-1. 8. Patients with adequately maintained organ function. Exclusion Criteria The study subject should be excluded if any one of the following condition exists. 1. Patients who have been without treatment for less than 3 weeks after prior treatment. 2. Patients who can be candidates for autologous peripheral blood stem cell transplantation at the discretion of the investigator. 3. Patients who received adequate prior treatments and did not respond to any of them. 4. Patient who received prior chemotherapy 3 regimens or more. 5. Patients with central nervous system (CNS) involvement or patients with clinical symptoms suggestive of CNS involvement. 6. Patient with serious active infection. 7. Patient with serious complication. 8. Patient with complication or medical history of serious cardiac disease. 9. Patient with serious gastrointestinal symptoms. 10. Patient with malignant pleural effusion, pericardial effusion, or ascites retention. 11. Patients positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, or HIV antibody. 12. Patient with serious bleeding tendency. 13. Patient with a fever of 38.0°C or higher. 14. Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema. 15. Patients with active multiple primary cancer or patients with a history of other malignant cancer within the past 5 years, except for basal cell cancer of the skin, squamous cell cancer, or cervical cancer in situ. 16. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia. 17. Patient who received bendamustin hydrochloride in the past. 18. Patients who received cytokine preparation such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 2 weeks before the examination at registration for this study. |
| Country | Name | City | State |
|---|---|---|---|
| Japan | Research Site | Akita | |
| Japan | Research Site | Chuo-ku | Tokyo |
| Japan | Research Site | Fukuoka | |
| Japan | Research Site | Fukushima | |
| Japan | Research Site | Fukuyama | Hiroshima |
| Japan | Research Site | Ibaraki | |
| Japan | Research Site | Isehara | Kanagawa |
| Japan | Research Site | Izumo | Shimane |
| Japan | Research Site | Kobe | Hyogo |
| Japan | Research Site | Koto-ku | Tokyo |
| Japan | Research Site | Kumamoto | |
| Japan | Research Site | Kyoto | |
| Japan | Research Site | Maebashi | Gunma |
| Japan | Research Site | Matsuyama | Ehime |
| Japan | Research Site | Mibu | Tochigi |
| Japan | Research Site | Nagasaki | |
| Japan | Research Site | Nagoya | Aichi |
| Japan | Research Site | Okayama | |
| Japan | Research Site | Osaka | |
| Japan | Research Site | Osakasayama | Osaka |
| Japan | Research Site | Ota | Gunma |
| Japan | Research Site | Sapporo | Hokkaido |
| Japan | Research Site | Sendai | Miyagi |
| Japan | Research Site | Shibukawa | Gunma |
| Japan | Research Site | Shibuya-ku | Tokyo |
| Japan | Research Site | Shimotsuke | Tochigi |
| Japan | Research Site | Shinagawa-ku | Tokyo |
| Japan | Research Site | Toyoake | Aichi |
| Japan | Research Site | Yamagata |
| Lead Sponsor | Collaborator |
|---|---|
| SymBio Pharmaceuticals |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall Response Rate | Complete Response (CR) + Partial Response (PR) Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007) | up to 30 weeks | |
| Secondary | Complete Response (CR) Rate | Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007) | up to 30 weeks | |
| Secondary | Progression Free Survival (PFS) | PFS = day of the first PFS event - day of start of study treatment + 1 | up to 30 weeks | |
| Secondary | Duration of Response (DOR) | DOR is the period from the date of achieving CR, or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% Confidence Interval (CI ) were calculated using Greenwood's formula. | up to 30 weeks | |
| Secondary | Overall Survival (OS) | Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. | up to 30 weeks. |